 |
2016-05-16 19:16:08 good ●●●●●●al ●●●●●● nline ●●●●●● ●●●●●● UPDATE: In an ●●●●●●or note, Cowen & Co ●●●●●●t Simos S●●●●●●dis wrote that the move ●●●●●●●●●●●● Eisai’s ●●●●●●r ●●●●●●ment to ●●●●●●ting the drug, ●●●●●● that it will ●●●●●●e an ●●●●●●ental ●●●●●●cial ●●●●●●age to Belviq that Vivus will have to deal with, and makes Vivus' need for a ●●●●●● ●●●●●●rship even ●●●●●●r". H●●●●●●, he added that "this ●●●●●● in the ●●●●●●cial ●●●●●●place does not ●●●●●● the drug's ●●●●●●al ●●●●●●e, and this is where we ●●●●●●e Belviq is at a ●●●●●●●●●●●●". ●●●●●●a ●●●●●●s ●●●●●●tion A●●●●●●●●●●●●n ●●●●●●als did not ●●●●●●n the ●●●●●● of ●●●●●●●●●●●● ●●●●●●ms, but they ●●●●●●ized that full ●●●●●●●●●●●●ment for other ●●●●●●duals will be ●●●●●●ble on Oct. 1under the P●●●●●● P●●●●●●ion and A●●●●●●ble Care Act, ●●●●●●●●●●●●n as O●●●●●●re. |